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Abstract
Background: Decisions about medical indication are a relevant problem in pediatrics. Difficulties arise from the high prognostic 
uncertainty, the decisional incapacity of many children, the importance of the family, and conflicts with parents. The objectivity of 
judgments about medical indication has been questioned. Yet, little is known about the factors pediatricians actually include in their 
decisions.
Aim: Our aims were to investigate which factors pediatricians apply in deciding about medical indication, and how they manage 
conflicts with parents.
Design: We performed a qualitative focus group study with experienced pediatricians. The transcripts were subjected to qualitative 
content analysis.
Setting/participants: We conducted three focus groups with pediatricians from different specialties caring for severely ill children/
adolescents. They discussed life-sustaining treatment in two case scenarios that varied according to diagnosis, age, and gender.
Results: The decisions about medical indication were based on considerations relating to the individual patient, to the family, and to 
other patients. Individual patient factors included clinical aspects and benefit–burden considerations. Physicians’ individual views and 
feelings influenced their decision-making. Different factors were applied or weighed differently in the two cases. In case of conflict with 
parents, physicians preferred solutions aimed at establishing consensus.
Conclusion: The pediatricians defined medical indication on a case-by-case basis and were influenced by emotional reasoning. In 
contrast to prevailing ethico-legal principles, they included the interests of other persons in their decisions. Decision-making strategies 
should incorporate explicit discussions of social aspects and physicians’ feelings to improve the transparency of the decision-making 
process and reduce bias.
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What is already known about the topic?
•• Decisions about medical indication in pediatrics are particularly challenging, and different views and values may lead to 
conflicts with parents.
•• Despite legal regulations and guidelines, uncertainties exist about how to define medical indication in individual cases.
•• There is little research on how decisions are made in clinical practice and what influences pediatricians in decision-making.
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What this paper adds?
•• This study underlines the complexity and the value-laden nature of decisions about medical indication. Pediatricians’ per-
sonal views and emotions as well as the interests of others play a role in the decision-making process.
•• Pediatricians define medical indication differently, depending on the individual case.
•• In cases of conflict, pediatricians prefer consensus-oriented strategies or comply with parental decisions.
Implications for practice, theory, or policy
•• The results of this study can inform the development of decision-making models and policies.
•• Decision-making frameworks should adopt a two-step approach, focusing on the review of the medical indication before 
entering the dialogue with the patient and parents.
•• Decision-making strategies, ethics consultations, and professional education should incorporate discussions of the impact 
of other people’s interests and of pediatricians’ attitudes and feelings on decisions about medical indication in order to 
increase awareness and reduce bias.
Introduction
Decisions on life-sustaining treatment (LST) for children 
and adolescents raise important medical and ethical ques-
tions: What factors determine whether an intervention is 
considered medically indicated? Who decides what is in 
the best interests of a child without decision-making 
capacity? How can conflicts with parents be resolved? 
Legislation and bioethical guidelines in Germany and 
Switzerland emphasize the role of the medical indication 
in treatment decisions.1–7 Medical indication is defined as 
the physician’s professional judgment about which treat-
ments are in the best interests of the patient.1,8 An interven-
tion is considered medically indicated if (1) there is a 
realistic chance to achieve the intended treatment goal 
(treatment effectiveness) and (2) the treatment represents a 
benefit to the patient that outweighs its burdens (positive 
benefit–burden ratio).1,3,8 The medical indication is legally 
required for performing any medical procedure, in addi-
tion to patient/surrogate consent.1
The term medical indication is insufficiently precise, like 
the term futility, raising similar problems with regard to its 
definition and application.8–10 A main concern is that the deci-
sions include not only clinical aspects but also value judg-
ments by the physician.8–16 It has therefore been advocated to 
include the patient’s view in the benefit–burden assessment.8,9 
However, many pediatric patients are too young to form and 
express their own views. In these children, the caregivers’ 
evaluations necessarily gain weight. Conflicts can arise when 
physicians and parents disagree about what is in the child’s 
best interests.17,18 Moreover, many children who die have 
complex and rare life-limiting conditions with uncertain 
prognoses and unfamiliar illness trajectories.17–23
Despite legal regulations and guidelines, uncertainties 
and different views exist about how to define medical indi-
cation and how to manage conflicts with the family.8,24 
While medical indication is commonplace in clinical prac-
tice, little is known about how pediatricians understand 
and apply it in their current practice.
This study is part of a larger research project on advance 
care planning and LST decisions in pediatrics. It follows a 
prior study which revealed uncertainties and discomfort 
among pediatricians regarding LST decisions.25 In order to 
better understand and improve the practice of LST deci-
sion-making in complex medical situations, we wanted to 
study how pediatricians comprehend and approach medi-
cal indication, which factors they actually include in their 
decisions, and how they deal with parental dissent.
Methods
This study used a qualitative descriptive approach to 
explore how decisions about medical indication for LST 
are made in pediatrics. We collected information by low-
structured and case-based focus group discussions. Clinical 
case vignettes were used to stimulate focused discussions 
close to real practice, to elicit implicit views and avoid 
social acceptability bias.26 The research methods and their 
reporting follow the consolidated criteria for reporting 
qualitative research (COREQ).27 All raw data related to 
the study are available from the corresponding author.
Sampling
Three focus groups were conducted with experienced pedi-
atricians from various subspecialties in order to involve a 
variety of perspectives. Participants were selected by pur-
poseful sampling, based on the following prerequisites: (1) 
caring for severely ill children/adolescents; (2) leading 
position (chief resident, attending physician, head of 
department); and (3) interest in the research question.
Recruitment
Eligible persons were identified through gatekeepers and 
personal knowledge according to the above-mentioned 
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criteria. We chose two study sites (Munich/Germany and 
Lausanne/Switzerland) because they both have strong pedi-
atric intensive care and palliative care teams with significant 
experience in making LST decisions for children. The legal 
and ethical frameworks for medical decision-making in 
pediatrics are comparable at both sites. One focus group was 
held with participants of an advanced pediatric palliative 
medicine course in order to include pediatricians with spe-
cial interest in palliative care. None of the participants were 
provided any incentive for taking part in the study.
Data collection
The focus group discussions took place between May and 
July 2014. Participants received an information letter on 
the study background, methods, and data protection, and 
gave written consent to their participation. Two focus 
groups were chaired by the author M.F., an experienced 
pediatric oncologist and professor for pediatric palliative 
care. Focus group 3 was chaired by the author G.D.B., an 
experienced neurologist and palliative care physician, 
and director of a palliative care service. Authors J.D.L. 
and C.M. took field notes. The discussions followed a 
semi-structured interview guide, developed according to 
Helfferich,28 and discussed in various research groups 
with methodological, clinical, and bioethical expertise. 
The focus groups were audiotaped and transcribed verba-
tim. Words or phrases stressed by the interviewees were 
transcribed in capital letters. The study protocol and 
materials were reviewed and approved by the institu-
tional review board of the Munich University Hospital 
(No: 049-12). Lausanne waived the necessity of a second 
approval.
Participants were asked to discuss the medical indication 
of LST for two case scenarios based on real cases (Boxes 1 
and 2). The cases presented complex and in one case rare 
medical situations, which are often the setting for controver-
sial discussions on LST in pediatric practice. No definition of 
“medical indication” was given because the term is common-
place in Germany and Switzerland, and we did not want to 
unduly bias the participants’ own ways to use it in clinical 
practice. The case scenarios were highly different in order to 
identify a variety of factors and explore whether and how 
decision-making differs depending on the case. The vignettes 
provided necessary information about the patient’s medical 
condition and prognosis, but left space for participants to fill 
in details and bring up additional hypothetical factors.29,30
After reading the vignette together with the participants, 
they were asked, “How do you judge the medical indication 
for the treatment in question?” Each participant was asked 
to give a short statement, followed by an open discussion. 
Vignette 2 was divided into two parts with two subsequent 
treatment questions, read out and discussed after each other. 
Finally, the participants were asked—independently of the 
cases—how they would deal with parental dissent. A short 
self-administered questionnaire was distributed to collect 
personal information on participants’ age, sex, years of pro-
fessional experience, specialization, additional qualifica-
tions, and experience with the diseases. The discussions 
took about 60 min per case.
Data analysis
The transcripts of focus groups 1 and 2 were analyzed by 
the authors J.D.L. and C.M. Focus group 3 (Swiss) was 
analyzed and interpreted in French by the bilingual authors 
Box 1. Case vignette 1.
Patient features
Age An 8-week-old boy
Diagnosis Spinal muscular atrophy-type I (SMA-I), genetically assured
Prognosis Rapid deterioration of muscular function, death likely in first year of life due to respiratory insufficiency
Medical history Little movements in last weeks of pregnancy, considerable deterioration of motor function at 6 weeks 
after birth
Current status Beginning dysphagia and nutritional disturbance, progressive respiratory insufficiency
 Patient seems attentive and communicates non-verbally with parents
Family One elder sister (3 years)
 Parents emotionally distressed, think about the impact on their child’s and their own life
Discussed treatment options and outcomes
Invasive and non-
invasive ventilation
Significant prolongation of survival, at best into second decade of life (for invasive ventilation)
Loss of motor functions, pulmonary infections, severe osteoporosis, scoliosis, impaired language 
production, normal cognitive development
Palliative care Alleviation of respiratory distress by palliative interventions, opioids, and benzodiazepines
Question asked How do you judge the medical indication for mechanical ventilation?
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J.D.L. and G.D.B. A qualitative content analysis was per-
formed,31 using the software MAXQDA-10. We extracted 
all information consecutively from the three focus groups 
that referred to factors considered for medical indication. 
Categories and subcategories were inductively developed, 
checking back with the original data. Category contents, 
coding rules, and prototype examples were defined to 
increase transparency and reliability. The category system 
was cross-validated, reviewed by the research team, and 
discussed in a multidisciplinary research meeting, result-
ing in no major revisions. The (sub)categories were com-
pared between the two case scenarios. Differences between 
focus groups were not systematically analyzed because 
this was not our research focus.
Results
In all, 17 participants were recruited according to the 
selection criteria. All participants had experience with at 
least one of the diseases presented. Table 1 lists the partici-
pants’ demographics.
Factors considered for medical indication
Participants based their assessment of the medical indica-
tion on their professional experience, case examples, and 
empirical data. They asked for more information, includ-
ing scientific evidence, expert input, and interdisciplinary 
discussions. In case 2, they advocated further diagnostic 
measures to reduce prognostic uncertainty.
Table 2 summarizes all factors participants considered 
when discussing the medical indication for LST in the two 
cases. The factors were categorized in those relating to 
treatment and prognosis, to the physician, patient or fam-
ily, as well as to ethical, legal, and economic aspects.
Participants considered the medical prognosis and 
treatment effectiveness in achieving goals such as life pro-
longation or symptom control. They also evaluated the 
anticipated benefits and burdens associated with the spe-
cific intervention. They discussed the patient’s presumed 
wishes and views, and took into account the parents’ per-
ception of their child. The consequences for the family, 
other patients, and society (e.g. economically) were also 
considered. Additionally, emotional reasoning and diffi-
culties with LST limitation played a role in the decision-
making. In the following, the factors considered will be 
described in more detail for each of the two cases.
Case 1: spinal muscular atrophy-type I
In this case about an infant with spinal muscular atrophy-
type I (SMA-1), treatment-related and prognostic factors, 
Box 2. Case vignette 2.
Part 1
Age A 15-year-old girl
Diagnosis Dyskeratosis congenita, diagnostically assured, caused by TERC-mutation that impairs telomere 
function
Prognosis Progressive loss of the self-renewal capacity of all stem cells, particularly of the hematopoietic system, 
skin, mucous membranes, and liver
 Risk of severe pulmonary disease, particularly in patients with previous blood stem cell transplantation
Medical history Diagnosis established at the age of 11 years
 Three blood stem cell transplantations for the treatment of bone marrow failure, graft-versus-host reaction
 Hospital admission 8 weeks ago, able to walk and express herself clearly at admission
Current status Chronic liver failure, beginning renal and respiratory insufficiency, transfer to intensive care unit
 Severe pain caused by osteoporosis and multiple fractures, hypercalcemia
 Increased ammonia level, somnolence shortly after hospital admission, episodes of delirium
Question asked How do you judge the medical indication for the liver transplantation?
Part 2
Further disease 
course after liver 
transplantation
Values of ammonia and parameters of liver and kidney function rapidly normalize after liver 
transplantation
No improvement of clinical condition, persisting somnolence, skeletal pain
Patient refuses to eat
Acute heart failure with severe arrhythmia, caused by myocardial fibrosis
Prognosis Possible damage to liver graft by heart failure, low chance of medical recompensation of cardiac 
function
Question asked How do you judge the medical indication for the heart transplantation?
TERC: telomerase RNA component.
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physician factors, family, and patient factors were particu-
larly important. Ethical and legal factors were also consid-
ered, but to a lesser extent.
Treatment-related and prognostic factors. These factors 
were highly relevant in this case. Discussed treatment 
goals included life prolongation, improvement of current 
symptoms (respiratory insufficiency), and quality of life. 
The participants focused particularly on the evaluation 
of the benefits and burdens of mechanical ventilation for 
the child. They discussed the treatment invasiveness and 
related burden, the prolonged life expectancy, the loss of 
Table 1. Sample characteristics (n = 17).
Focus group Represented pediatric disciplines Place of work Gender Age (years) Professional 
experience (years)
Focus group 1 Pediatric cardiology, pediatric neurology, 
pediatric hematology and oncology, 
pediatric critical care, pediatric palliative 
care, pediatric primary care
Munich, Germany Male = 5
Female = 1
M = 47
SD = 6.9
M = 18
SD = 5.5
Focus group 2 Pediatric cardiology, pediatric neurology, 
pediatric hematology and oncology, 
neonatology, pediatric critical care, 
pediatric palliative care, pediatric 
primary care, clinical ethics counseling
Würzburg/Kiel/
Heidelberg/
Munich, Germany
Innsbruck, 
Austria
Male = 3
Female = 3
M = 41
SD = 5.9
M = 11
SD = 6.5
Focus group 3 Pediatric cardiology, pediatric 
hematology and oncology, pediatric 
critical care, pediatric palliative 
care, pediatric primary care, neuro-
rehabilitation, clinical pharmacology
Lausanne, 
Switzerland
Male = 4
Female = 1
M = 43
SD = 9.4
M = 18
SD = 7.7
Total Male = 12
Female = 5
M = 44
SD = 7.5
M = 16
SD = 7.1
M: mean, SD: standard deviation.
Table 2. Factors considered in decisions about medical indication.
Thematic category Factors considereda
Treatment-related 
and prognostic 
factors
Treatment goal, available treatment options
Treatment invasiveness and treatment-related impairment, risk of complications and non-survival, necessary 
follow-up treatments, lacking prospect of better treatments in the future
Reversibility of damages, chance for symptom improvement
Expected disease course, life expectancy
Expected level of motor and cognitive functioning, expected communication abilities and capacity to consent
Anticipated quality of life: autonomy, participation in life, psychological suffering
Patient-related 
factors
Patient age, decision-making capacity
Underlying disease and causes of symptoms, comorbidities
Stability of current health status, symptom severity, cognitive situation
Previous symptoms and suffering, previous treatments and treatment outcomes
Patient’s (presumed) wishes, patient’s (presumed) subjective experience of the disease and psychological 
distress, treatment compliance
Family-related 
factors
Family context: siblings, cultural background
Family/parent wishes and attitudes
Burden on the family and coping resources
Physician-related 
factors
Difficulties withholding and withdrawing life-sustaining treatment, fear of over-treatment
Optimism, hope for medical progress or a miracle
Personal involvement in patient’s care, own emotional response, “gut feeling”
Professional specialization, own experience with similar patients, usual practice
Ethical and legal 
factors
Right for life, protection of life
Child’s best interests, harm avoidance
Distributive justice, respect to organ donor
Legislation allowing for treatment limitations
Economic factors Financial costs for society associated with provision of treatment/care resources
aListed order of reasons does not reflect priority.
Lotz et al. 965
motor function, the normal cognitive development, as 
well as the anticipated level of autonomy and participa-
tion in life. However, participants differed in their evalu-
ations of the consequences for the patient’s future quality 
of life:
Then, this brings up the question about the quality of life 
associated with this [life] prolongation. What we see in 
children with similar pathologies is that the restriction of 
autonomy and communication is so extreme that, in my 
opinion, there is indeed no medical indication for initiating 
[mechanical] ventilation in any case. (Pediatrician in neuro-
rehabilitation and pediatric palliative care)
They can have in fact a VERY satisfying life, also later. This 
has shaped me, and for this reason, I would in ANY case 
allow enough time in all of these children, and I would provide 
as much information as possible that mechanical ventilation, 
of whatever kind, is entirely feasible nowadays, also at home 
and on the road, in the airplane or wherever. (Pediatric critical 
care physician)
Patient factors. The participants took into account the 
patient’s incurable disease, normal cognitive function, cur-
rent medical condition, and age at death. It was considered 
easier to limit LST in an infant than in older children. 
However, there were also suggestions to initiate treatment 
and wait until the patient could be involved in the decision 
about his treatment. Participants discussed how the patient 
might view his situation at a more advanced age, after hav-
ing been treated with mechanical ventilation.
Family factors. Major consideration was given to the par-
ents’ views and preferences and their ability to cope with 
the situation (“what they can bear”). Some participants 
wished to discuss treatment options with the parents before 
deciding about the medical indication:
Well, I would literally RELY on parents’ assessment of their 
child’s existence on non-invasive or invasive ventilation with 
a tracheostoma in the critical care unit, so I could, perhaps, 
develop a recommendation based on the parents’ view. 
(Neonatologist experienced in pediatric oncology)
Physician factors. Participants’ individual attitudes, emo-
tional responses, and personal experience were also impor-
tant. Participants’ own discomfort regarding LST 
limitations was particularly important. They hesitated to 
withhold LST, pointing to the possibility of withdrawing it 
later. However, withdrawing LST once started was per-
ceived as very difficult, too. This ambiguity is well illus-
trated by two quotes from the same physician:
Of course, it is a difficult decision NOT to use an available 
therapy. […] It requires to show a lot more backbone [Note: 
German colloquial for courage] NOT to start. (Pediatric 
cardiologist)
What I consider difficult is: Once you go down the road of 
[mechanical] ventilation, you cannot really relinquish it. So 
this has to be really thought through before you can start on 
this journey. (Same pediatric cardiologist)
Ethical and legal factors. Participants relied on the legal 
right to limit LST, but morally questioned this right in 
the case of a child with normal intelligence and a poten-
tial life expectancy of over 20 years under LST. The 
child’s best interests were balanced against the family’s 
interests:
[I] think that as a physician, who actually advocates for the 
child, you have to be very careful not to do things for the 
parents that, at the same time, rather prolong the child’s 
suffering. […] and to be very clear: where do we relieve 
something for the child and where do we prolong suffering? 
(Pediatric neurologist)
Economic factors. Participants also referred to the resources 
necessary for the child’s care (e.g. care homes) and the 
associated costs for society.
Case 2: dyskeratosis congenita
In this case of a congenital disease with a high prognos-
tic uncertainty, participants found it difficult to assess 
the medical indication for the liver transplantation, but 
agreed that there was no indication for the subsequent 
heart transplantation. Similar factors were used in both 
treatment decisions, but some were evaluated differ-
ently. The participants focused on the patient’s medical 
condition and prognosis. Ethical factors differed from 
those in case 1. Physician factors were similar to those 
in case 1, but less important. Family factors were hardly 
addressed.
Treatment-related and prognostic factors. As in case 1, these 
factors were highly important in case 2. Discussed treatment 
goals included cure of the underlying disease and improve-
ment of current symptoms (e.g. liver failure, neurological 
symptoms). Factors relating to the medical prognosis and 
treatment effectiveness were particularly important, includ-
ing the anticipated disease course, the chance for cure, the 
reversibility of current symptoms—particularly the neuro-
logical symptoms—and the risk for treatment complica-
tions. Symptom reversibility was strongly doubted after the 
failure of the liver transplantation.
Patient factors. The participants focused on the patient’s 
diagnosis (disease involving multiple organs), her neu-
rological impairment, and medical history. No medical 
indication was established for the heart transplantation 
because of further deterioration of the patient’s condi-
tion and lacking neurological improvement after the 
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liver transplantation and because of the diagnostic 
uncertainties:
Well, I think, now [Note: after liver transplantation] at the 
latest, I would like to have an answer to the question: How can 
the neurological situation be explained? […] The child has 
been transplanted because she deteriorated neurologically, and 
it has not gotten better. And now the next organ fails and we 
have NO idea what is the cause. For me that would be a clear 
contra-indication to a heart transplantation. (Neonatologist 
and pediatric critical care physician)
It was considered particularly difficult to limit LST 
in an adolescent patient compared to infants or elderly 
people. The patient’s wishes were viewed as important. 
The participants asked about previously stated prefer-
ences or hoped to stabilize the patient in order to clarify 
her wishes.
Ethical and legal factors. Ethical considerations focused on 
distributive justice and the interest of other patients in 
cases of limited resources:
The waste of the organ transplant, this is a rather strong 
argument, […] we have the possibility to refuse. Maybe this 
is the only exception where you can do it because we have 
the argument of the benefit to someone else. (Pediatric 
primary care physician)
Dealing with parental dissent
Participants discussed several options for resolving con-
flicts with parents, listed in Table 3. They tended to com-
ply with parental decisions. The main reasons for accepting 
parents’ refusal of indicated LST were discussed: the 
necessity of parental consent and parents’ right to reject 
clinical recommendations. The main reasons for comply-
ing with parents’ requests of non-indicated LST included 
parents’ suffering, physicians’ fear of legal consequences, 
and avoidance of doctor shopping. However, the partici-
pants most frequently favored consensus solutions that 
evolve from continued discussions with parents. Physicians 
were also willing to provide medically non-indicated LST 
for a certain period of time to open doors for shared 
decision-making:
To be faced with a different opinion by the parents who wish 
to initiate treatment while we think it is not worth it—this 
simply means that the process of acceptance is not easy, so we 
have to give time, we can always negotiate about temporary 
measures. (Pediatric cardiologist)
Table 3. Options for dealing with parental dissent regarding life-sustaining treatment.
Favored option for dealing 
with parental dissent
Justificationsa
Override parental 
decisions
Justification for overriding parental decisions when parents refuse indicated LST:
Physicians’ medical expertise, duty to deliver care according to best evidence
Protection of the child’s best interests
Justification for overriding parental decisions when parents request non-indicated LST:
Avoidance of harm to the child
Other patients’ interests in case of limited resources
Clear and reassuring legislation, refusal to act against own conscience
Comply with parental 
decisions
Justification for complying with parental decisions when parents refuse indicated LST:
Parents’ decision-making power, necessity of parental consent
Uncertain clinical judgments, recommendations that may be rejected
Parents’ better ability to assess the child’s presumed wishes
Justification for complying with parental decisions when parents request non-indicated LST:
Avoidance of doctor shopping and associated harm for the child
Parents’ well-being
Close relationship with parents, difficulties withstanding parents’ firm demands
Subjectivity of medical decisions
Court rulings expected to be in favor of parents, fear of legal consequences
Search consensus: give 
parents time, continue 
negotiations, and shared 
decision-making
Justification for searching consensus with parents when parents refuse indicated LST:
More time for parental coping
Justification for searching consensus with parents when parents request non-indicated LST:
More time for parental coping
Importance for parents to see the disease progressing
Suggest change of 
physician
Justification for change of physician when parents request non-indicated LST:
Duty to offer all possibilities, broken trust
Chance that a second physician confirms the decision
LST: life-sustaining treatment.
aListed order of reasons does not reflect priority.
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In cases of unsolvable conflicts with parents, it was 
suggested to change the physician in charge because of 
broken trust or in the hope to reach an agreement with the 
confirmation by a second opinion.
Discussion
This study examined the factors pediatricians include in 
their decision-making on medical indication regarding 
LST. The results show that pediatricians base their deci-
sions on multiple factors and do not completely adhere to 
the narrow legal definition of “medical indication.” The 
data also demonstrate that decisions about medical indica-
tion are more than a purely clinical judgment of the treat-
ment effectiveness and benefit–burden ratio. In fact, these 
decisions are intermingled with value judgments. This 
matches with predominant normative conceptions.1,3,8 The 
benefit–burden judgment has been described in the litera-
ture as physicians’ indication (in contrast to medical indi-
cation) and is comparable with Schneiderman’s notion of 
qualitative futility.8,32,33 This component is the major cause 
for criticism of the indication concept, because it depends 
on the physician’s individual values.8,11,16,34 It has been 
shown that physicians differ in their attitudes and practices 
regarding LST.35–41 Moreover, they rate the quality of life 
of severely impaired children lower than the children 
themselves or their parents.42–44 Our results demonstrate 
that benefit–burden judgments are subjective and are 
sometimes more influenced by physicians’ individual 
experience with single patients than by medical evidence.
Furthermore, our participants were influenced by their 
own emotional responses. This may be even more impor-
tant in the setting of a real case when personal involvement 
is higher. Individual views and feelings should be made 
explicit in the decision-making process, for example, 
through ethics consultations, in order to increase pediatri-
cians’ awareness, and to reduce emotional interference and 
subjectivity of decisions.
Our participants also included the interests of the fam-
ily in their decision-making, as has been shown in previ-
ous studies.45,46 They considered aspects of social justice 
such as harms for other patients in cases of limited 
resources. However, these are considerations from the 
point of view of social ethics, while the medical indication 
refers to the individual patient.8
In case of parental dissent, the participants tended to 
comply with parents’ decisions, although performing non-
indicated treatment on parents’ request does not conform 
to the principle of best interests of the child as defined by 
German and Swiss law.1,4,5 However, this has been consid-
ered as ethically justified in cases of extreme psychologi-
cal suffering of the family, as long as it does not cause 
harm for the child.47
One of the reasons mentioned by our participants for 
complying with parents’ decisions was the uncertainty and 
subjectivity of the medical indication. In cases such as 
ours, when the child cannot express its own view, the bur-
den of surrogate decision-making is perceived as extremely 
challenging by physicians. Thus, some of our participants 
tended to pursue LST—even in situations like SMA-1—
until the child might reach decision-making capacity.
Most of our participants clearly favored strategies that 
focus on negotiation and consensus with parents, as advo-
cated by medical societies and shown in previous studies 
(shared decision-making).5,45,48 In order to facilitate such 
discussions, pediatricians’ communication skills need to 
be improved by communication trainings and guides.17 
Adult approaches to communication in conflictual meet-
ings with relatives could be adapted.49 Moreover, advance 
care planning may provide a means for mitigating conflicts 
because it focuses on a guided process of information 
transfer, exploration of wishes and values, and negotiation 
of goals, aiming at shared decision-making and good qual-
ity of communication.50,51 However, in case of unsolvable 
conflicts, it is the obligation of the physician to appeal to 
the court when he fears serious harm to the child.7,12,52
Our data show that pediatricians do not apply a univer-
sal definition of medical indication, but define it on a case-
by-case basis. This suggests that universal definitions of 
medical indication may be difficult to apply in concrete 
cases.11,12,53 Instead, procedural approaches which focus 
on determining the medical indication and resolving con-
flicts in individual cases may be more useful.9,11,12,53,54 
Various interventions are helpful to provide normative 
guidance and improve the decision-making practice: insti-
tutional policies, tools for ethical decision-making, ethics 
consultation, legal and ethical education, and supervision 
for physicians.8,55–58 They should incorporate explicit dis-
cussions of factors that may unduly bias the decisions (e.g. 
personal feelings, interests of others). Decision-making 
frameworks should adopt a two-step approach, focusing 
on the review of the medical indication in relation to the 
individual patient, before entering the dialogue with the 
parents. In addition, utilization of clinical practice guide-
lines and decision support tools needs to be fostered 
through education and integration into organizational 
structures.59,60 Previous data show that guidelines are 
insufficiently known and underutilized.24,60–62 This was 
also the case in our study.
Our study has several limitations. First, the focus groups 
differed in several aspects. This was intended to broaden 
the spectrum of different practices and attitudes, and was 
compensated by performing data analysis across groups. 
The gender imbalance in our study reflects the actual gen-
der distribution among pediatricians in senior positions in 
Central Europe. Second, performing the study in two coun-
tries with different languages might constitute a limitation. 
However, the ethico-legal context for LST decisions in 
children is similar in both countries. Correspondingly, data 
analysis did not indicate significant differences between the 
German and Swiss discussions, which argues in favor of 
the validity of the results. Third, case vignettes were used to 
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explore pediatricians’ decision-making, which may reduce 
generalizability to real-life situations. However, available 
evidence shows a high level of concordance between phy-
sicians’ responses to vignettes and real-life situations.63–65 
Moreover, vignettes are useful to reduce social desirability 
bias and elicit implicit views, and less hypothetical than 
abstract questions on attitudes and practices.26,29,30,65–67 
Fourth, the case vignettes present rather rare and complex 
clinical situations, and the information provided for the dis-
cussion was necessarily limited. However, this reflects real 
situations pediatricians face in many severely ill children, 
where decisions on the medical indication are often based 
on limited medical evidence.
Conclusion
The results of this qualitative study help us to better com-
prehend how pediatricians define medical indication in the 
context of LST. Our results can increase the awareness of 
how various factors influence pediatricians’ decisions. 
They may inform the practice of clinical ethics consulta-
tion and assist in the development of tools to guide ethical 
decision-making for LST in pediatrics. Procedural 
approaches to medical indication might provide better 
guidance in concrete cases than universal definitions. The 
applicability of developed instruments needs to be verified 
and ensured. It is particularly important to openly address 
physicians’ personal views and feelings in order to prevent 
undue bias in decision-making.
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